Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.

@article{Allaume2012RetargetingOR,
  title={Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.},
  author={Xavier Allaume and Nazim El-Andaloussi and Barbara Leuchs and Serena Bonifati and Amit Kulkarni and Tiina Marttila and Johanna Kaufmann and Dirk M Nettelbeck and Juergen Kleinschmidt and Jean Rommelaere and Antonio Marchini},
  journal={Journal of virology},
  year={2012},
  volume={86 7},
  pages={3452-65}
}
The rat parvovirus H-1PV is a promising anticancer agent given its oncosuppressive properties and the absence of known side effects in humans. H-1PV replicates preferentially in transformed cells, but the virus can enter both normal and cancer cells. Uptake by normal cells sequesters a significant portion of the administered viral dose away from the tumor target. Hence, targeting H-1PV entry specifically to tumor cells is important to increase the efficacy of parvovirus-based treatments. In… CONTINUE READING